Geratherm Medical AG

Earnings Release • Jul 28, 2009

News Details

Ad-hoc | 28 July 2009 14:37

Geratherm Medical AG: Geratherm Medical achieves best first-half result so

Geratherm Medical AG / Half Year Results

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

DGAP ad hoc report: Geratherm Medical achieves best first-half result so
far

Ad hoc report in compliance with Section 15 WpHG transmitted by the DGAP -
an enterprise of Equity Story AG. The content of the report is the
responsibility of the issuer.

• Sales revenue 6.3 million EUR +34%

• EBITDA 1,115 kEUR +163%

• EBIT 964 kEUR +262%

• Result for the period 912 kEUR +208%

• Result per share 20 cents (QII 18 cents)

Geschwenda, 28 July 2009 - In the first half of 2009, Geratherm Medical
succeeded in achieving the highest level of sales and earnings so far. The
basis for the company's growth of +34% is the above-average level of demand
for newly introduced products and the EU prohibition on mercury in force
since April 2009. The expansion of sales resulted in a significant rise in
the company's earnings. The operating result and also the after-tax result
increased three-fold in comparison with the same period last year. All in
all, the statement of income for the shareholders of the parent company
amounted to 20 cents per share for the first half-year.

For the rest of the year, the board expects the current dynamic development
to continue. If the general circumstances remain the same, Geratherm
Medical's sales and hence also its earnings can be expected to increase
further. This assessment does not take account of additional demand owing
to the possible spread of swine flu.

Publication of the detailed first-half figures is scheduled for 20 August
2009.

Short company profile

Geratherm Medical is an internationally operating medical products
enterprise with the business areas 'Temperature Management', 'Cardio' and
'Respiratory'.

Our company's roots are in temperature measurement in the medical sphere.
In this business area we offer a broad spectrum of products, most of which
have unique selling points. We supply our customers/patients with
high-quality products ranging from thermometers to complex warming systems
for use in the operating theatre and by emergency rescue services. In the
Cardio business area we concentrate on the development of products for the
detection of atrial fibrillation as a measure to prevent strokes. The
Respiratory segment develops and markets products for the assessment of
pulmonary function.

Geratherm shares have been listed in the Prime Standard segment of the
Frankfurt Stock Exchange since the year 2000. Geratherm Medical continues
to be represented in the German Entrepreneurial Index and in the German
Health-Care Index.

Geratherm Medical AG, Investor Relations

Fahrenheitstraße 1, 98716 Geschwenda

Tel. +49 (0)36205/98 111, E-Mail: info@geratherm.com www.geratherm.com

Emittent: Geratherm Medical AG, Fahrenheitstraße 1, 98716 Geschwenda
Deutschland

Tel. 036205/98 111 Fax: 036205/98 115

ISIN : DE 000 549 562 6

WKN : 549 562

Börsen : Frankfurter Wertpapierbörse /Geregelter Markt/Prime Standard

Börse: Freiverkehr in Berlin-Bremen, Düsseldorf, Hamburg, München,
Stuttgart

• Ende der Mitteilung -
  28.07.2009 Financial News transmitted by DGAP

---

Language: English
Issuer: Geratherm Medical AG
Fahrenheitstraße 1
98716 Geschwenda
Deutschland
Phone: +49 (0)36205 98-0
Fax: +49 (0)36205 98-1 15
E-mail: info@geratherm.com
Internet: www.geratherm.com
ISIN: DE0005495626
WKN: 549562
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Hamburg, Stuttgart

End of News DGAP News-Service

---